Internal Medicine, Hematology & Oncology · Chicago, IL
NPI
1619981768
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
676 N Saint Clair St Ste 2140
Chicago, IL, 60611
Phone (312) 695-0990
Groups this clinician bills Medicare through
Medicare paid, 2024
$27K
289 services
Medicare patients, 2024
202
Average age 70
Drug cost, 2024
$5.7M
939 prescriptions
Company payments, 2025
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brandon J McMahon was code 99215 (office e&m - established), 115 times for 76 patients. In total Brandon J McMahon billed 289 services in 11 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 115 | 76 | $106.46 | $12K |
| 99214 Office E&M - Established | Facility | 50 | 41 | $62.30 | $3,115 |
| 99205 Office E&M - New | Facility | 32 | 32 | $134.35 | $4,299 |
| 99204 Office E&M - New | Facility | 22 | 22 | $86.26 | $1,898 |
| 99222 Hospital E&M - Initial | Facility | 18 | 18 | $102.90 | $1,852 |
By year: 2022 $26K for 297 services; 2023 $26K for 291 services; 2024 $27K for 289 services.
Medicare prescription drug claims, 2024
In 2024, the drug Brandon J McMahon prescribed most often to Medicare patients was Hydroxyurea, with 184 prescriptions and refills. In total Brandon J McMahon wrote 939 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 184 | 434 | 44 | $6,195 |
| Jakafi Ruxolitinib Phosphate | 140 | 140 | 17 | $2.3M |
| Xarelto Rivaroxaban | 90 | 227 | 27 | $125K |
| Eliquis Apixaban | 63 | 126 | 16 | $71K |
| Pegasys Peginterferon Alfa-2a | 61 | 61 | Under 11 | $230K |
| Besremi Ropeginterferon Alfa-2b-Njft | 56 | 56 | Under 11 | $934K |
| Warfarin Sodium Generic | 53 | 124 | 22 | $530 |
| Tranexamic Acid Generic | 23 | 31 | Under 11 | $2,551 |
| Cyclosporine Modified Cyclosporine, Modified | 23 | 32 | Under 11 | $3,191 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 21 | 21 | Under 11 | $748 |
| Doptelet Avatrombopag Maleate | 19 | 19 | Under 11 | $361K |
| Anagrelide Hcl Generic | 18 | 46 | Under 11 | $3,311 |
| Ojjaara Momelotinib Dihydrochloride | 18 | 18 | Under 11 | $516K |
| Promacta Eltrombopag Olamine | 17 | 17 | Under 11 | $388K |
| Ayvakit Avapritinib | 17 | 17 | Under 11 | $515K |
Brand drugs: 534 claims; generic drugs: 405 claims; opioid claims: 25.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brandon J McMahon $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.